Basic Female Viagra Information

• INN (International Nonproprietary Name): The term “Female Viagra” generally refers to flibanserin (Addyi) and, less commonly, bremelanotide (Vyleesi), both of which are approved for treating hypoactive sexual desire disorder (HSDD) in premenopausal women.
• Brand Names Available In Canada (English): Addyi (flibanserin) and Vyleesi (bremelanotide) are known brand names internationally, with Addyi sold as 100 mg film-coated tablets and Vyleesi as a pre-filled single-use autoinjector 1.75 mg; some sildenafil products marketed as “female Viagra” (for example Vibasuva F) are sold in other markets such as India but are not approved for HSDD by major regulators.
• ATC Code: Flibanserin — G02CX01. Bremelanotide — G02CX06.
• Forms & Dosages: Flibanserin 100 mg oral tablets, taken once nightly at bedtime; bremelanotide 1.75 mg subcutaneous single-use autoinjector, given ≥45 minutes before sexual activity, up to one dose per 24 hours and eight doses per month.
• Manufacturers In Canada (English): Not specified for domestic manufacturers; internationally Addyi is from Sprout Pharmaceuticals (U.S.) and Vyleesi is from AMAG Pharmaceuticals (U.S.).
• Registration Status In Canada (English): Not specified in this dataset for active Health Canada DIN registration; clinicians should verify the Health Canada Drug Product Database before prescribing.
• OTC / Rx Classification: Addyi and Vyleesi are prescription only (Rx) in regulated markets; some sildenafil generics marketed as “female Viagra” are OTC in a few countries but are not approved for HSDD.

Key Findings From Recent Trials

Worried whether these medicines really help or are just marketing?

Recent systematic reviews and post‑marketing observational reports from 2022–2025 consolidated earlier randomised controlled trial evidence showing that flibanserin (Addyi) and bremelanotide (Vyleesi) produce modest but statistically significant improvements in validated desire scales for premenopausal women with acquired, generalized HSDD.

These studies also reported small absolute benefits in satisfying sexual events compared with placebo.

Real‑world observational reports emphasise high inter‑individual variability in response.

Clinical experience shows benefit tends to be limited to a subset of carefully selected patients who meet strict diagnostic criteria for acquired, generalized HSDD.

Primary trial outcomes focused on sexual desire questionnaires such as the Female Sexual Function Index and event‑based measures.

Time to measurable benefit differs by drug class.

Flibanserin typically requires nightly dosing and several weeks of treatment before patients or clinicians may notice improvement.

Bremelanotide produces an acute effect when injected prior to sexual activity, with onset consistent with its pharmacology.

Safety signals remained consistent across 2022–2025 reports.

Flibanserin is associated with somnolence and dizziness, and its interaction with alcohol raises hypotension and syncope concerns.

Bremelanotide commonly causes nausea and flushing and may affect blood pressure, prompting advice for monitoring in at‑risk patients.

Regulatory advisories to date reiterate the need for careful screening and monitoring before and during use.

For patients asking about female Viagra, these results frame realistic expectations: modest gains for some people, not a universal cure.

Clinical Mechanism Of Action

What do these drugs actually do in the brain and body?

Flibanserin (Addyi) is a central nervous system agent that acts on serotonin and dopamine pathways to rebalance neurochemical drivers of sexual desire.

It is taken nightly rather than used acutely.

Bremelanotide (Vyleesi) is a melanocortin receptor agonist that is given as an as‑needed subcutaneous injection and can acutely enhance sexual response.

At the scientific level, flibanserin displays a 5‑HT1A agonist and 5‑HT2A antagonist profile.

This pharmacology results in downstream increases in dopaminergic and noradrenergic tone in mesolimbic circuits that are implicated in sexual desire.

The mechanism explains the delayed onset and the logic of nightly dosing at 100 mg at bedtime.

Bremelanotide works by stimulating melanocortin receptors centrally and peripherally, producing an acute pro‑sexual effect when administered before sexual activity.

Pharmacokinetics and metabolism differ between the two.

Flibanserin is orally bioavailable and undergoes hepatic metabolism, creating interactions with CYP3A4 inhibitors and posing concerns in severe hepatic impairment.

Bremelanotide is absorbed subcutaneously from its autoinjector and carries specific hepatic and renal considerations that warrant caution in impairment.

These mechanistic differences explain why flibanserin requires daily adherence while bremelanotide is for intermittent use.

Scope Of Approved And Off‑Label Use

Can these products be prescribed in Canada and who are they for?

Internationally, the FDA approves Addyi (flibanserin) and Vyleesi (bremelanotide) for premenopausal women with acquired, generalized HSDD.

Health Canada and DIN status should be confirmed before prescribing or dispensing.

Health‑system availability in Canada is limited and prescribers should verify current DIN listings and provincial formulary positions such as ODB, BC PharmaCare, and RAMQ.

When products are not listed domestically, off‑label or importation pathways are sometimes used by patients and clinicians.

Some Canadian patients and clinics explore importation or private‑clinic access when local availability is restricted.

In other markets, some sildenafil generics are marketed as “female Viagra,” but sildenafil is not approved by major regulators for HSDD in women.

Clinicians and pharmacists must counsel patients about the limited evidence and safety uncertainties when patients request sildenafil or unregulated online products.

Documentation of informed consent and discussion of legal and safety issues is important when considering non‑standard pathways.

Dosage Strategy

How should dosing be planned and what adjustments matter?

Follow product monographs where available for dosing guidance.

Flibanserin standard dosing is 100 mg orally at bedtime, taken at the same time each night for continuous therapy.

Bremelanotide dosing is 1.75 mg subcutaneous injected at least 45 minutes before sexual activity, with a limit of one dose per 24 hours and eight doses per month.

Adherence to timing is critical for both safety and efficacy.

Flibanserin’s bedtime dosing reduces daytime somnolence and aligns with its delayed onset of effect.

Bremelanotide should be injected before planned sexual activity to produce an acute response.

For severe hepatic impairment, flibanserin is contraindicated and must not be used.

No paediatric indication exists and elderly data are limited, so these groups should be treated only with specialist input when necessary.

In renal or moderate hepatic insufficiency, consult the product monograph and consider specialist referral.

Medication reconciliation is essential to identify CYP3A4 inhibitors or inducers that change flibanserin exposure and to adjust therapy accordingly.

Safety Protocols

What safety checks should happen before a pharmacist or prescriber hands these over?

Absolute contraindications apply universally and include hypersensitivity to the active ingredient, pregnancy, and breastfeeding.

Specific to flibanserin, concurrent alcohol use is contraindicated due to increased risk of hypotension and syncope.

Flibanserin is also contraindicated with strong CYP3A4 inhibitors and in severe hepatic impairment.

Bremelanotide requires caution in patients with uncontrolled hypertension or cardiovascular disease because of potential blood pressure effects.

Common adverse effects reported post‑market include dizziness, somnolence, nausea, fatigue, insomnia and dry mouth for flibanserin.

Bremelanotide commonly causes nausea, flushing, injection‑site reactions and headache.

Canadian pharmacovigilance reports echo international trends, so pharmacists should report observed adverse events to Health Canada.

Screening questions should include liver disease history, alcohol use, current medications that affect CYP3A4, and cardiovascular risk factors.

Interaction Mapping

What should patients avoid eating or drinking, and which drugs must be checked?

Alcohol interaction with flibanserin is paramount and must be clearly avoided from treatment initiation and during use.

Co‑consumption of alcohol increases the risk of hypotension and syncope when combined with flibanserin.

Although large or high‑fat meals may minimally affect absorption, the primary counselling point is alcohol avoidance.

Drug combinations flagged by Health Canada for flibanserin include strong or moderate CYP3A4 inhibitors such as certain antifungals and macrolide antibiotics.

Concomitant use with these agents increases flibanserin exposure and should be avoided.

Serotonergic polypharmacy risk should be considered when patients take antidepressants or other serotonergic agents.

Bremelanotide interactions are primarily related to blood pressure effects and clinicians should monitor co‑medication with antihypertensives and consider specialist input when needed.

Pharmacists should perform a thorough medication review and document counselling about these interactions.

Patient Experience Analysis

Do patients in Canada feel these drugs are worth the trouble?

Large, nationally representative Canadian surveys specific to Addyi or Vyleesi are limited.

Smaller clinic audits and patient‑reported outcome registries from 2022–2025 show mixed satisfaction.

A subgroup of patients reports clinically meaningful benefit, while many discontinue due to side effects or minimal perceived improvement.

Cost and access are commonly cited barriers to continuation in Canadian practice.

In community pharmacy and online forums, patients frequently discuss importation, private clinic access, and confusion over the term “female Viagra.”

Community pharmacists at major chains report frequent questions about availability, safety and insurance coverage.

Counselling from pharmacists emphasises the limited evidence for broad use and the need for careful patient selection and monitoring.

Distribution And Pricing Landscape

How easy is it for Canadian patients to get these medicines and what will they pay?

Availability in major pharmacy chains such as Shoppers, Rexall, Jean Coutu and London Drugs varies and depends on DIN verification.

When products are not locally listed, many pharmacists advise manufacturer or importation pathways, or referral to private clinics that may provide injections for bremelanotide.

Online international pharmacies sometimes ship Addyi or Vyleesi, but these channels carry risks related to unlicensed products and customs or Health Canada import rules.

Provincial drug plans like ODB, BC PharmaCare and RAMQ typically require a DIN and formulary listing for coverage.

Out‑of‑pocket costs can therefore be substantial for many patients.

Some Canadian patients compare prices with U.S. markets where pricing and insurance coverage can be more favourable, but cross‑border procurement requires awareness of Canadian importation rules and customs checks.

Remember that in our online pharmacy, female viagra is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Alternative Options

What else can help if these drugs are not suitable or preferred?

There is no widely accepted DIN‑approved “female Viagra” equivalent that matches the HSDD indication in Canada beyond the branded options discussed.

Pharmacologic alternatives tend to address specific causes rather than generalized HSDD.

Topical vaginal oestrogens remain first‑line for menopausal genitourinary symptoms that impair sexual comfort and desire.

Hormone replacement or transdermal therapy may help when hormonal deficiency is a driver of low desire.

Behavioural therapies, couples counselling and sex therapy are effective non‑pharmacologic options that address psychosocial drivers.

Pros of flibanserin and bremelanotide include targeted indication for premenopausal acquired, generalized HSDD and RCT backing.

Cons include modest benefit sizes, safety monitoring requirements, and limited availability or coverage.

Non‑drug therapies carry low adverse event risk and address root causes, but require time and access to trained therapists.

Regulatory Status

How does Health Canada handle new drugs like these and what packaging rules matter?

Health Canada requires a New Drug Submission with clinical evidence of safety and efficacy and assignment of a Drug Identification Number (DIN) before lawful marketing.

Clinicians should confirm current NDS outcomes and DINs via Health Canada’s Drug Product Database prior to prescribing or dispensing.

For sale in Canada, a DIN is mandatory and packaging must meet Canadian bilingual labelling requirements in English and French as well as Good Manufacturing Practices.

Imported products lacking a DIN may be used under special access or personal importation rules but clinicians must document counsel and patient consent.

Always verify registration status and provide clear written information when guiding patients about imported or unlicensed products.

Consolidated FAQ

Here are quick answers to the most common questions patients ask at the pharmacy.

• Is there a female Viagra approved in Canada? Internationally Addyi (flibanserin) and Vyleesi (bremelanotide) are FDA‑approved for premenopausal HSDD, but Canadian DIN and formulary status should be checked in the Health Canada database for current availability.
• Can I use sildenafil for low desire? Sildenafil is not approved for HSDD in women and evidence for benefit is limited; many products marketed as “female Viagra” are sildenafil generics sold in other markets without HSDD approval.
• What are the main risks? Flibanserin carries alcohol‑related hypotension and syncope risk and CNS depression; bremelanotide commonly causes nausea and may affect blood pressure, so screen cardiovascular and hepatic history.
• Will insurance cover it? Coverage depends on a product having a DIN and provincial formulary listing; many patients will face out‑of‑pocket costs if a product is not listed.

Visual Guide

What should a simple infographic for patients include?

Include dosing timelines that contrast nightly flibanserin 100 mg with as‑needed bremelanotide 1.75 mg injection given before sexual activity.

Show a provincial coverage map that highlights the need for a DIN and formulary listing for public reimbursement.

Add a safety flowchart prompting screening for liver disease, alcohol use, and cardiovascular risk before prescribing.

Illustrate purchase channels: local pharmacy with DIN, special access or personal importation, and U.S. cross‑border purchase with notes on customs and legalities.

Design bilingual labelling blocks in English and French and use clear icons for prescription (Rx), contraindications (stop sign), and monitoring (stethoscope).

Storage And Transport

How should patients store these medicines at home and what to check when importing?

Flibanserin should be stored at room temperature between 20–25°C and protected from moisture in its original container.

Bremelanotide should be protected from light and heat and stored at room temperature within the 15–30°C range, following autoinjector storage instructions.

Neither product routinely requires refrigerated shipping for normal storage.

When products are shipped internationally, tracking for temperature excursions and inspection for tampering is advised.

Advise patients who import medicines to inspect packaging, verify expiry and DIN labelling where present, and to avoid products with damaged seals.

Guidelines For Proper Use

What practical steps should pharmacists take when counselling patients?

Confirm the indication is acquired, generalized HSDD in a premenopausal woman before recommending treatment.

Review the patient’s full medication list for CYP3A4 inhibitors and other interacting agents.

Counsel on strict alcohol avoidance with flibanserin and on proper injection technique and blood pressure monitoring for bremelanotide.

Document counselling in the patient record and provide written instructions aligned with the product monograph.

Check provincial formularies for any prior‑authorization requirements and encourage multidisciplinary care with sexual medicine or mental health referrals where appropriate.

For imported products, guide patients through legal importation steps and advise against unregulated online purchases.

Delivery Across Canada (English)

Final Notes And Next Steps

Many patients ask for clear guidance: these medicines can help some people but are not universally effective.

Selection relies on a confirmed diagnosis of acquired, generalized HSDD and careful review of liver, alcohol and cardiovascular history.

Pharmacists should use the product monograph as the primary reference for dosing, contraindications and drug interactions.

Report suspected adverse events to Health Canada to contribute to post‑market safety data.

When patients request alternative products marketed as female Viagra, counsel that sildenafil is not approved for HSDD and that online generics often lack supportive evidence and regulatory approval.

For access questions, check the Health Canada Drug Product Database for DIN status and consult provincial formularies for coverage criteria.

When patients choose importation routes, document counselling and advise them about legal and safety considerations.

For persistent or complex cases, refer to sexual medicine or mental health specialists to ensure multidisciplinary care.